LQDA
Liquidia Corporation · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers):
holder breadth +6.2% ·
share flow +17.5% ·
net new positions +5.9%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 99 | +23 | 36.66M | $2.92B | +26 | −3 |
| Q1 2026 | 79 | -1 | 26.51M | $999.68M | +6 | −8 |
| Q4 2025 | 81 | 0 | 26.44M | $911.45M | +1 | n/a |
| Q3 2025 | 17 | +1 | 21.94M | $498.92M | +1 | n/a |
| Q2 2025 | 13 | -2 | 14.83M | $184.82M | n/a | −2 |
| Q1 2025 | 12 | 0 | 5.71M | $84.24M | n/a | n/a |
| Q4 2024 | 12 | +4 | 4.81M | $56.51M | +4 | n/a |
| Q3 2024 | 7 | -2 | 2.07M | $20.68M | +1 | −3 |
| Q2 2024 | 9 | n/a | 2.26M | $27.08M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 5.23M | +6.9% | $118.90M | 0.0% | ▲ Add | 2 | SEC ↗ ×13 |
| 2 | The Vanguard Group ✦ (passive) | 3.96M | +10.2% | $90.08M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | Goldman Sachs Group ✦ | 2.78M | n/a | $63.27M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 1.91M | +4.5% | $43.52M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.61M | +14.4% | $36.56M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 1.49M | +916.1% | $33.83M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 1.01M | n/a | $22.89M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 8 | Millennium Management ✦ | 974.70K | +4636.4% | $22.16M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Fidelity (FMR) ✦ | 907.68K | -0.7% | $20.64M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 484.75K | New | $11.02M | 0.0% | New | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 449.56K | +21.2% | $10.22M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 434.10K | -41.9% | $9.87M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Marshall Wace ✦ | 332.29K | -49.7% | $7.56M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Wellington Management ✦ | 239.58K | +17.4% | $5.45M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 15 | T. Rowe Price ✦ | 60.01K | +87.2% | $1.37M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 16 | JPMorgan Chase ✦ | 55.84K | n/a | $1.27M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 17 | AQR Capital Management ✦ | 12.78K | -13.2% | $290,595 | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $11.02M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 242 holders, 61.34M shares, $2.26B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.30K sh · $207,932
Officer · 13.69K sh · $389,948
Officer · 9.22K sh · $262,529
Officer · 8.86K sh · $252,418
Officer · 5.25K sh · $149,378
Officer · 1.10K sh · $31,356
Officer · 18.94K sh · $539,354
Officer, Director · 32.74K sh · $932,549
Officer · 5.89K sh · $167,804
Director · 235.48K sh · $6.39M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology